Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis

Ludovic Lemée, Eva Hong, Manuel Etienne, Ala-Eddine Deghmane, Valérie Delbos, Aude Terrade, Gilles Berthelot, Francois Caron, Muhamed-Kheir Taha, Ludovic Lemée, Eva Hong, Manuel Etienne, Ala-Eddine Deghmane, Valérie Delbos, Aude Terrade, Gilles Berthelot, Francois Caron, Muhamed-Kheir Taha

Abstract

The prevention of meningococcal disease may be improved by recombinant vaccines such as 4CMenB and rLP2086 that target the factor H binding protein (fHbp), an immunogenic surface component of Neisseria meningitidis present as one of three variants. Whether such vaccines decrease carriage of invasive isolates and thus induce herd immunity is unknown. We analyzed the genetic diversity and levels of expression of fHbp among 268 carriage strains and compare them to those of 467 invasive strains. fhbp gene sequencing showed higher proportions of variants 2 and 3 among carriage isolates (p<0.0001). Carriage isolates expressed lower levels of fHbp (p<0.01) but that remain high enough to predict targeting by antibodies against fHbp particularly in group B isolates belonging to the frequent hypervirulent clonal complexes in Europe and North America (cc32, cc41/44, cc269). This suggests that fHbp targeting meningococcal vaccines might reduce, at least in part, the acquisition of some hyperinvasive isolates.

Trial registration: ClinicalTrials.gov NCT01214850.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Phylogenetic relationships between carriage and…
Figure 1. Phylogenetic relationships between carriage and invasive isolates.
On the right side of the figure the carriage isolates are displayed (n = 124). The invasive isolates for which full MLST data were available (n = 126) are on the left side of the figure. Relationships and clustering of typing data were performed using the START package available through (http://pubmlst.org).
Figure 2. Schematic representation of the levels…
Figure 2. Schematic representation of the levels of expression of fHbp overtime among carriage isolates.
Data were obtained from 80 subjects for whom two positive pharyngeal swabs were available at a mean of 1 weak interval. For each subject, the data were expressed as ratio of the expression of fHbp from the fist sample and the reference isolate and linked by a solid line to the ratio of the expression of fHbp from the second sample and the reference isolate.
Figure 3. Distribution of relative levels of…
Figure 3. Distribution of relative levels of expression of fHbp among carriage and invasive isolates.
Data were expressed as ratios of the expression for each strain compared to a reference strain a scatter plots (filled gray circles) and mean values (black lines). The clonal complexes (cc) to which belong the tested isolates are indicted under each group of scatter plots.

References

    1. Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis . Lancet 369: 2196–2210.
    1. Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, et al. (2004) Distribution of Serogroups and Genotypes among Disease-Associated and Carried Isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 42: 5146–5153.
    1. Zarantonelli ML, Lancellotti M, Deghmane AE, Giorgini D, Hong E, et al. (2008) Hyperinvasive genotypes of Neisseria meningitidis in France. Clin Microbiol Infect 14: 467–472.
    1. Brehony C, Jolley KA, Maiden MC (2007) Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 31: 15–26.
    1. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM (2007) Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 15: 233–240.
    1. Harrison LH, Trotter CL, Ramsay ME (2009) Global epidemiology of meningococcal disease. Vaccine 27 Suppl 2: B51–63.
    1. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, et al. (2013) Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis.
    1. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, et al. (2013) A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 31: 1569–1575.
    1. Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, et al. (2013) Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine 31: 1113–1116.
    1. Caron F, du Chatelet IP, Leroy JP, Ruckly C, Blanchard M, et al. (2011) From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 11: 455–463.
    1. Delbos V, Lemee L, Benichou J, Berthelot G, Taha MK, et al. (2013) Meningococcal carriage during a clonal meningococcal B outbreak in France. Eur J Clin Microbiol Infect Dis.
    1. Kellogg DS Jr, Peacock WL Jr, Deacon WE, Brown L, Pirkle DI (1963) Neisseria gonorrhoeae. I. Virulence Genetically Linked to Clonal Variation. J Bacteriol 85: 1274–1279.
    1. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95: 3140–3145.
    1. Taha MK, Giorgini D, Ducos-Galand M, Alonso JM (2004) Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol 42: 4158–4163.
    1. Vazquez JA, Arreaza L, Block C, Ehrhard I, Gray SJ, et al. (2003) Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother 47: 3430–3434.
    1. Hong E, Giorgini D, Deghmane AE, Taha MK (2012) Functional impacts of the diversity of the meningococcal factor H binding protein. Vaccine 31: 183–189.
    1. Jolley KA, Chan MS, Maiden MC (2004) mlstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics 5: 86.
    1. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, et al. (2009) Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B Neisseria meningitidis . J Infect Dis 200: 379–389.
    1. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, et al. (2011) Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 79: 970–981.
    1. Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, et al. (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197: 737–743.
    1. Claus H, Maiden MC, Wilson DJ, McCarthy ND, Jolley KA, et al. (2005) Genetic analysis of meningococci carried by children and young adults. J Infect Dis 191: 1263–1271.
    1. Marsh JW, Shutt KA, Pajon R, Tulenko MM, Liu S, et al. (2011) Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. Vaccine 29: 6049–6058.
    1. Taha MK (2013) Immunisation against meningococcus B. Lancet. 382: 936.
    1. Loh E, Kugelberg E, Tracy A, Zhang Q, Gollan B, et al. (2013) Temperature triggers immune evasion by Neisseria meningitidis . Nature 502: 237–240.
    1. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, et al. (2013) Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13: 416–425.
    1. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Bmj 326: 365–366.

Source: PubMed

3
Tilaa